Clinical Trial

Sorafenib Combined With Venetoclax as Pre-emptive Therapy Strategy for MRD+ AML: a Prospective, Single-arm, Multicenter Clinical Study

Name: Sorafenib Combined With Venetoclax as Pre-emptive Therapy Strategy for MRD+ AML: a Prospective, Single-arm, Multicenter Clinical Study — clinical trial record (NCT07264010)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Phase 2/3

View on ClinicalTrials.gov →

Summary

The purpose of this study is to explore the efficacy and safety of sorafenib combined with venetoclax as pre-emptive therapy strategy for measurable residual disease persisting acute myeloid leukemia.

Trial Details

NCT Number	NCT07264010
Lead Sponsor	Nanfang Hospital, Southern Medical University
Conditions	Acute Myeloid Leukaemia (AML), Measurable Residual Disease (MRD)
Enrollment	87 participants
Start Date	2025-12-01
Primary Completion	2026-12-30 (estimated)
Study Completion	2028-12-30 (estimated)
Updated on ClinicalTrials.gov	2025-12-04